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Abstract
Animal models of cardiovascular diseases allow to inves-
tigate relevant pathogenetic mechanisms in detail. In the
present study, the mutations Asp175Asn and Glu180Gly
in a-tropomyosin (TPM1), known cause familiar hypertro-
phic cardiomyopathy (FHC) were studied for changes in
hemodynamic parameters and spontaneous baroreflex
regulation in transgenic rats in comparison to transgenic
and non-transgenic controls by telemetry. Heart rate var-
iability (HRV) and blood pressure variability (BPV) were
analyzed using time- and frequency domain, as well as
non-linear measures. The dual sequence method was
used for the estimation of the baroreflex regulation. In
transgenic rats harboring mutated TPM1, changes in
HRV were detected during exercise, but not at rest. Both
mutations, Asp175Asn and Glu180Gly, caused increased
low frequency power. In addition, in animals with muta-
tion Asp175Asn a reduced total HRV was observed. BPV
did not show any differences between all transgenic ani-
mal lines. During exercise, a strong increase in the
number of bradycardic and tachycardic fluctuations
accompanied with decreased baroreflex sensitivity (BRS)
was detected in animals with either TPM1 mutation,
Asp175Asn or Glu180Gly. These data suggest, that the
analysis of cardiac autonomic control, particularly of
baroreflex regulation, represents a powerful non-invasive
approach to investigate the effects of subtle changes in
sarcomeric architecture on cardiac physiology in vivo. In
case of mutations Asp175Asn or Glu180Gly in TPM1,
early detection of alterations in autonomic cardiac control
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could help to prevent sudden cardiac death in affected
persons.
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Introduction
During the last decade, substantial efforts were made to
discover the genetic reasons of cardiovascular diseases.
Based on this genetic information, subsequent studies
can now be initiated to investigate the pathogenetic
effects of disease-causing mutations on cardiac physi-
ology. In this context, advanced technologies in biosignal
processing provide enhanced methods to study cardiac
function in vivo in a non-invasive way. In particular, their
application in studies of cardiovascular diseases in ani-
mal models represents a useful approach for getting
insights into relevant pathogenetic mechanisms, which
will be elucidated in this Part II of a bipartite series on
this general topic. A detailed description of the biosignal
processing tools was given by Part I w23x.
Based on the conflicting results on autonomic nervous
control in patients with familiar hypertrophic cardiomyo-
pathy (FHC) w5, 7, 21x, transgenic rats overexpressing
either mutation Asp175Asn or Glu180Gly in TPM1 were
investigated for the hemodynamic effects on heart rate,
aortic blood pressure, and spontaneous baroreflex re-
gulation caused by these two missense mutations. The
transgenic rat strains used in the present research were
established to study the effect of low-level overexpres-
sion of human a-tropomyosin (TPM1), harboring muta-
tion Asp175Asn or Glu180Gly, on cardiac physiology in
vitro as well as in vivo w22x. So, autonomic cardiac control
in these conditions could be investigated in those trans-
genic animals at rest as well as during exercise, including
the periods before and after completing the exercise pro-
tocol in running wheels.
Materials and methods
The various analytical methods for heart rate variability
(HRV), blood pressure variability (BPV), and baroreflex
sensitivity (BRS) analyses are described in Part I w23x of
this bipartite report on autonomic cardiac control in ani-
mal models of cardiovascular diseases. Therefore, this
section now supplements the details on the animal
model.
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(B) HRV parameters at the end of the training protocol.
A (WT) B (Asp175Asn) C (Glu180Gly) PKW
MEANNN 133.43"3.93 138.33"2.60 151.63"6.19† -0.05
SDNN 6.56"1.27 5.49"0.30‡ 9.31"0.85§ -0.05
RMSSD 4.44"0.46* 2.96"0.23‡ 5.21"0.45 -0.01
LF 0.0008"0.0001 0.0012"0.0003‡ 0.008"0.002†§ -0.01
HF 0.0009"0.0001 0.0008"0.0002‡ 0.002"0.001† -0.01
LF/HF 0.92"0.08*§ 1.63"0.19‡ 3.49"0.69† -0.001
POLVAR3 0.05"0.01* 0.44"0.03‡ 0.10"0.05 -0.01
HRV parameters of transgenic animals were calculated from 1 h recordings during exercise. See w23x for detailed description of the
parameters.
* p-0.05 A (WT) vs. B (Asp175Asn).
† p-0.05 A (WT) vs. C (Glu180Gly).
‡ p-0.05 B (Asp175Asn) vs. C (Glu180Gly).
§ p-0.05 begin vs. end of training.
Mean values were calculated from 6 animals.
Table 1 HRV parameters during exercise.
(A) HRV parameters at the beginning of the training protocol.
A (WT) B (Asp175Asn) C (Glu180Gly) PKW
MEANNN 133.22"3.33 139.94"2.62 144.82"3.98 n.s.
SDNN 6.59"0.84 6.35"0.13 6.94"0.42 n.s.
RMSSD 3.72"0.09* 2.86"0.14‡ 4.00"0.21 -0.01
LF 0.0012"0.0002 0.0011"0.0004‡ 0.0038"0.0008† -0.01
HF 0.0008"0.0001 0.0006"0.0002‡ 0.0015"0.0002† -0.01
LF/HF 1.49"0.18 1.71"0.16 2.57"0.49 n.s.
POLVAR3 0.04"0.01* 0.43"0.06‡ 0.15"0.03† -0.01
Animal care and exercise
The transgenic rats were prepared as previously
described w22x. Six animals of each transgenic line and
six non-transgenic controls underwent the training pro-
cedure in ‘‘passive’’ running wheels which were driven by
an electric motor. In parallel, six animals of each trans-
genic line and six non-transgenic control animals were
analyzed at rest. The telemetry and data acquisition sys-
tem equipped with Dataquest LabPRO software system
was used as suggested by the manufacturer (Data Sci-
ences Inc., St. Paul, MN, USA). The system and the sen-
sor implantation procedure are described by Brockway
et al. w4x.
Statistics
Group summaries are expressed as mean value " stan-
dard error. The non-parametric Kruskal-Wallis test was
used to detect intergroup differences, whereas differenc-
es between two groups were analyzed using Mann-Whit-
ney U-test. In all tests, the criterion for statistical
significance was Bonferroni-Holm corrected p-0.05.
Results
HRV, BPV, and spontaneous baroreflex activity were ana-
lyzed in transgenic rat lines, overexpressing either the
human wild-type (WT) TPM1 (line A (WT)), or TPM1 with
mutation Asp175Asn wline B (Asp175Asn)x, or with muta-
tion Glu180Gly wline C (Glu180Gly)x; time domain and fre-
quency domain parameters, as well as non-linear
measures as described in Part I w23x were determined.
Hemodynamic parameters were detected at rest and
during exercise at the beginning as well as after com-
pleting an exercise protocol in running wheels.
No differences were seen in HRV between sedentary
animals of all three transgenic lines A (WT), B
(Asp175Asn), and C (Glu180Gly) at the beginning of the
training procedure as well as after completing the exer-
cise protocol. At the end of the exercise protocol, how-
ever, changes in HRV were observed in animals of both
mutant lines, B (Asp175Asn) and C (Glu180Gly). As
shown in Table 1B, reduced total HRV was observed in
line B (Asp175Asn) compared to line C (Glu180Gly) and
the transgenic control line A (WT) based on the deter-
mination of the root mean square of successive differ-
ences (RMSSD) and the intermittently decreased
variability POLVAR3, one time domain and one symbolic
dynamics parameter, respectively. At the same time, a
1.8-fold increase in the low/high frequency component
ratio (LF/HF) was detected in line B (Asp175Asn) com-
pared to line A (WT). In comparison, line C (Glu180Gly)
is characterized by a 10-fold elevation of the low fre-
quency component (LF) and a 3.8-fold increase in the LF/
HF ratio. These changes in HRV parameters at the end
of the exercise protocol observed in both mutant lines,
B (Asp175Asn) and C (Glu180Gly), reached levels of sig-
nificance (Table 1B), but were either already detected or
somehow indicated to rise at the beginning of the exer-
cise protocol (Table 1A). Figures 1–3, showing represen-
tative 1 h recording strips of beat-to-beat intervals for
animals of line A (WT), B (Asp175Asn), and C (Glu180Gly)
during exercise near the end of the protocol, illustrate
the reduced total HRV in line B (Asp175Asn) and the
increased LF component of HRV in line C (Glu180Gly).
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Figure 1 Beat-to-beat heart rate and blood pressure recording of line A (WT).
One hour recording strip of beat-to-beat (BB) intervals and blood pressure values (BP) of a rat of line A (WT) during exercise at the
end of the training procedure are shown on the top. Below, the patterns of the corresponding bradycardic (bottom left) and tachycardic
(bottom right) baroreflex fluctuations are demonstrated. Bars represent average bradycardic/tachycardic BRS.
Figure 2 Beat-to-beat heart rate and blood pressure recording of line B (Asp175Asn).
Same as Figure 1 but now for a rat of line B (Asp175Asn).
The investigation of the blood pressure (BP) regulation
revealed no differences in mean BP values and in BPV
parameters between animals of all three transgenic lines
A (WT), B (Asp175Asn), and C (Glu180Gly) at rest and
during exercise, as demonstrated here for representative
BP recordings of animals under physical load (Figures
1–3).
The analysis of the spontaneous baroreflex activity
showed a strong influence of the baroreflex on BP reg-
ulation in animals of both mutant lines, B (Asp175Asn)
and C (Glu180Gly), compared to transgenic controls. In
line C (Glu180Gly), the number of bradycardic and tachy-
cardic baroreflex events, estimated using the dual
sequence method w23x, was increased 7-fold and 9-fold,
respectively. In line B (Asp175Asn), the number of brady-
cardic and tachycardic events was elevated 2.5-fold and
3-fold, respectively (see also Figures 1–3, bottom). The
comparison of baroreflex indices before and after the
physical training protocol in running revealed a more pro-
nounced positive training effect on baroreflex regulation
in transgenic controls compared to both mutant trans-
genic lines: While the sensitivity of baroreflex regulation
remained unchanged in all three transgenic rat lines, the
number of bradycardic and tachycardic events was ele-
vated 2-fold in line A (WT), but only by about 25% in lines
B (Asp175Asn) and C (Glu180Gly) (Table 2).
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Figure 3 Beat-to-beat heart rate and blood pressure recording of line C (Glu180Gly).
Same as Figure 1 but now for a rat of line C (Glu180Gly).
Table 2 Spontaneous baroreflex parameters during exercise.
(A) Spontaneous baroreflex parameters at the beginning of the training protocol.
A (WT) B (Asp175Asn) C (Glu180Gly) PKW
Brady events 81.75"14.17 211.20"26.16† 565.5"78.12* -0.001
Tachy events 60.75"8.77 186.20"20.03† 571.7"86.17* -0.001
Brady slope 5.03"1.26 3.54"0.60 2.82"0.24 n.s.
Tachy slope 4.32"1.14 2.47"0.16 2.38"0.09* -0.01
(B) Spontaneous baroreflex parameters at the end of the training protocol.
A (WT) B (Asp175Asn) C (Glu180Gly) PKW
Brady events 159.25"26.60‡ 243.00"26.12† 718.83"106.28* -0.001
Tachy events 114.25"17.08‡ 242.66"24.66† 673.66"55.83* -0.001
Brady slope 4.55"0.99 2.95"0.37 3.09"0.48* -0.01
Tachy slope 5.54"1.34 2.41"0.50 2.36"0.16* -0.01
Spontaneous baroreflex parameters of transgenic animals were calculated from 1 h recordings during exercise. ‘‘Brady events’’ stands
for the number of all bradycardic baroreflex events, ‘‘tachy events’’ for the number of all tachycardic baroreflex events, ‘‘brady slope’’
for the average bradycardic slope, and ‘‘tachy slope’’ for the average tachycardic slope. For detailed description of these parameters,
see w23x.
* p-0.05 A (WT) vs. C (Glu180Gly).
† p-0.05 B (Asp175Asn) vs. C (Glu180Gly).
‡ p-0.05 begin vs. end of training.
Mean values were calculated from 6 animals.
Analyzing the baroreflex regulation in resting animals,
a reduced BRS was detected in line B (Asp175Asn) com-
pared to line C (Glu180Gly) shown by a decreased aver-
age bradycardic slope (Table 3A). In this animal line,
reduced BRS is compensated by an increased number
of bradycardic events. After completing the training pro-
tocol, in animals of line B (Asp175Asn) baroreflex regu-
lation recovered as indicated by an increase in the
average bradycardic slope accompanied with the nor-
malization of the number of bradycardic events (Table
3B). At the same time, in line B (Asp175Asn) the baro-
reflex remained impaired as demonstrated by a strong
increase in the number of tachycardic events (Table 3B).
In comparison, in line C (Glu180Gly) baroreflex regulation
was not affected by physical training. In line A (WT), a
reduced number of bradycardic events accompanied
with an unchanged average bradycardic slope reflects a
positive training effect in these control animals (Table 3).
In all transgenic animals, the number of bradycardic
and tachycardic events was markedly increased in ani-
mals at rest in comparison to animals under physical load
(Tables 2 and 3). At the same time, only in transgenic
control animals of line A (WT) a strong increase in BRS
was observed during exercise compared to rest. This
increase in BRS is most likely based on the generally
elevated BPV in all transgenic rat lines during exercise
compared to rest (data not shown).
There were no significant differences in HRV, BPV, and
BRS between the transgenic line A(WT) and non-trans-
genic controls (data not shown).
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Table 3 Spontaneous baroreflex parameters at rest.
(A) Spontaneous baroreflex parameters before starting the training protocol.
A (WT) B (Asp175Asn) C (Glu180Gly) PKW
Brady events 1938.5"289.9 2453.2"619.8 1978.6"295.7 n.s.
Tachy events 1900.5"258.4 1797.6"480.3 1848.0"250.6 n.s.
Brady slope 1.96"0.17 1.69"0.24† 2.40"0.45 -0.01
Tachy slope 2.07"0.11 2.23"0.31 2.16"0.24 n.s.
(B) Spontaneous baroreflex parameters after completing the training protocol.
A (WT) B (Asp175Asn) C (Glu180Gly) PKW
Brady events 1325.0"193.8‡ 1978.6"414.1‡ 1924.5"230.4* -0.001
Tachy events 1707.3"344.2 2853.4"590.0‡ 1971.5"186.6* -0.001
Brady slope 2.06"0.27 2.21"0.26 2.46"0.16* -0.01
Tachy slope 1.69"0.12 1.77"0.33 2.36"0.19 n.s.
Spontaneous baroreflex parameters of transgenic animals as shown in Table 2 but now calculated from 2 h recordings at rest.
Discussion
In the present study, transgenic rats overexpressing
TPM1 with one of the two disease-causing mutations
Asp175Asn and Glu180Gly were studied for changes in
HRV, BPV, and BRS. The data show that the analysis of
cardiac autonomic control (particularly of baroreflex reg-
ulation) by using advanced signal processing tools rep-
resents a sensitive approach to discriminate between the
effects of point mutations within a single sarcomeric pro-
tein on cardiac function in vivo.
Changes of HRV parameters were detected in trans-
genic rats with either mutation Asp175Asn or Glu180Gly
in TPM1 compared to transgenic controls. During exer-
cise, in both mutant lines, B (Asp175Asn) and C
(Glu180Gly), increased LF power and elevated LF/HF
ratio were observed (Table 1). At the same time, for line
B (Asp175Asn) but not for line C (Glu180Gly), a decrease
of total HRV was shown, which is known to be associ-
ated with a poor prognosis in patients with different heart
diseases w11, 16x. Compared with mutation Glu180Gly,
mutation Asp175Asn represents a so-called ‘‘hot spot’’
mutation of the human disease, which was detected in
five unrelated families w6, 22x and shows a more severe
clinical phenotype w18x. Accordingly, in our previous
study, transgenic rats with mutation Asp175Asn dem-
onstrated pronounced alterations in cardiac physiology
than animals with mutation Glu180Gly w22x: Only cardiac
skinned-fiber preparations of line B (Asp175Asn) dem-
onstrated reduced Ca2q sensitivity. In cardiomyocytes of
line B (Asp175Asn), increased frequency and amplitude
of spontaneous Ca2q waves suggest an increase in intra-
cellular Ca2q concentration compensating for the
reduced Ca2q sensitivity of isometric force generation. As
a consequence, increased intracellular Ca2q might lead
to a ‘‘hypercontractile’’ state of the myofilament system
in line B (Asp175Asn). Interestingly to note that FHC is
usually accompanied with impaired left ventricular dia-
stolic function and secondary left atrial overloading w3,
9x. Thus, modulation of atrial and ventricular stretch-
mediated heart rate control, such as the Bainbridge
reflex, may be one of the factors responsible for both
decreased HRV and alteration of autonomic nervous
activity w8x.
Further, the analysis of the spontaneous baroreflex
activity revealed a strong influence of the baroreflex on
BP regulation in the transgenic rats with either mutation
Asp175Asn or Glu180Gly in TPM1 compared to trans-
genic controls. During exercise, in lines B (Asp175Asn)
and C (Glu180Gly) a decreased BRS was accompanied
by an increase in the number of bradycardic and tachy-
cardic fluctuations. Furthermore, after completing the
training protocol, resting rats of line B (Asp175Asn), but
not line C (Glu180Gly), showed a strong increase in the
number of tachycardic fluctuations (Table 3B). These
data suggest frequent BP declines in animals with muta-
tion Asp175Asn, known as to have a more severe phe-
notype in human w18x and to alter cardiac function in vitro
to a higher extent than mutation Glu180Gly w22x. Fre-
quent episodes of BP decline in line B (Asp175Asn) cor-
respond well with data obtained from clinical studies with
FHC patients. Exercise hypotension was observed in
one-third of patients with FHC w13x, due to an exagger-
ated paradoxic fall in systemic vascular resistance, pos-
tulated to be related to the activity of left ventricular
mechanoreceptors w19x. Possibly, abnormal local left
ventricular wall stresses during exercise and central
hypovolemia may be responsible for left ventricular
mechanoreceptor activation. Similar abnormal reflex
responses were observed in patients with vasovagal syn-
cope w20x and severe heart failure w1x.
Sudden cardiac death is the most prominent feature of
FHC, although the relevant mechanisms are still incom-
pletely understood. The data of the present study sug-
gest that for mutation Asp175Asn and Glu180Gly in
TPM1 several factors might trigger sudden cardiac
death:
(i) It was shown that in FHC episodes of hypotension,
particularly during or soon after exertion, are asso-
ciated with an increased risk of sudden cardiac
death w14x. The mechanism might be an abnormal
behavior of the left ventricular mechanoreceptors
during central blood volume underloading. To com-
pensate for these alterations of BP regulation, strong
baroreflex activity is needed as shown here for both
mutant rat lines B (Asp175Asn) and C (Glu180Gly).
(ii) The increase in LF/HF ratio and LF power in lines B
(Asp175Asn) and C (Glu180Gly) can be considered
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as a reduced vagal activity and/or increased sym-
pathetic activity known to be associated with life-
threatening arrhythmias during myocardial ischemia
w10, 17x. In parallel, in FHC patients who have sur-
vived cardiac arrest, electrophysiological testing has
demonstrated that sinus node dysfunction and
inducible ventricular arrhythmias are common w12x.
(iii) In our previous study, it was shown that skinned-
fiber preparations of line B (Asp175Asn) demonstrat-
ed reduced Ca2q sensitivity, which is compensated
by elevated intracellular Ca2q concentration w22x. An
increase in intracellular Ca2q concentration could
activate transient inward currents generally assumed
to be arrhythmogenic w15x. Interestingly, mutations
in thin filament proteins (TPM1, troponin T), in con-
trast to mutations in thick filament proteins (b-myo-
sin heavy chain, myosin-binding protein C), are
characterized by a higher percentage of sudden car-
diac death w2x.
In summary, the analysis of the autonomic cardiac reg-
ulation represents a sensitive approach which may be
able to discriminate between distinct FHC causing muta-
tions within a single sarcomeric protein. In this context,
the role of baroreflex regulation for early diagnosis and
disease control in human has to be further investigated.
In particular, clinical studies should be performed in
cohorts with a defined genotype to investigate autonom-
ic cardiac regulation for individual FHC causing muta-
tions at rest and during exercise. Furthermore, the value
of autonomic imbalance in predicting susceptibility to
arrhythmias and sudden cardiac death and as a potential
and independent marker of the disease should be
addressed. The advanced signal processing tools used
in this work proved to be very appropriate for such more
extended research efforts.
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